rewirebio.iobenchmarks
Dataset subset

Six held-out trials with overall survival

OAK, POPLAR, IMpower133, IMvigor010, IMvigor210 and IMbrave150, evaluated for overall survival.

Evaluation results

10 evaluations · 10 results. Different protocols are not a single leaderboard.

Filter evaluations

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configurationProtocol and datasetFindingEvidence and details
Configuration: BulkFormer 147M (Ladon report comparator)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.63 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

BulkFormer, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'BulkFormer', label 'OS 1.63'
Configuration: BulkRNABert, published Hugging Face checkpoint (Ladon report comparator)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.55 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

BulkRNABert, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'BulkRNABert', label 'OS 1.55'
Configuration: Clinical covariates encoded by BMRetriever-7B (Ladon report baseline)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.61 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 5/6 trials scored (IMbrave150 has no patient-specific clinical covariates, so its clinical-only hazard ratio is not estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Clinical covariates (BMRetriever), held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Clinical covariates (BMRetriever)', label 'OS 1.61'
Method: Differential gene expression signature (Ladon report)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.52 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Differential gene expression, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Differential gene expression', label 'OS 1.52'
Configuration: Ladon, survival mid-trained, ridge Cox fitted on TCGA and other trials (held-out trials)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.97 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Ladon', label 'OS 1.97'
Configuration: Ladon + clinical covariates, summed standardised risk scores (held-out trials)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
2.15 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (IMbrave150 uses Ladon alone in the combined predictor.)

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon + clinical covariates, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'Ladon + clinical covariates', label 'OS 2.15'
Method: Isoform TPM features (Ladon report)Protocol: Held-out trials, OS hazard ratio of higher- against lower-risk half, geometric mean over six trials
Dataset subset: Six held-out trials with overall survival
1.29 Hazard ratio (hazard ratio, higher-risk half against lower-risk half at the median predicted risk, overall survival, Cox stratified by treatment arm, Efron ties, full follow-up; equal-trial geometric mean over six trials)
unitless · higher

Uncertainty: Not reported by the source: Per-trial dots and a bar only; no interval is printed.

Coverage: 6/6 trials scored (All trials estimable.)

Author-reported evaluation · Source checked
Methods, coverage and source

TPM · matched TCGA, held-out trials OS hazard ratio

ladon-20261115-protocol-trials-os-hazard-ratio

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 3 (page 7), row 'TPM · matched TCGA', label 'OS 1.29'
Method: Differential gene expression signature (Ladon report)Protocol: Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool
Dataset subset: Six held-out trials with overall survival
0.595 Concordance index (Uno's C-index, overall survival, mean over six trials weighted by evaluated patients; training pool TCGA plus non-trial cohorts plus other trials (largest pool, about 18k samples))
unitless · higher

Uncertainty: Not reported by the source: No interval is printed for this value.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

DGE, held-out trials OS Uno C-index, largest training pool

ladon-20261115-protocol-trials-os-uno-weighted

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 5 (page 9), legend 'DGE 0.595', training stage '+ trials' (about 18k samples)
Method: Hallmark GSEA pathway signature (Ladon report)Protocol: Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool
Dataset subset: Six held-out trials with overall survival
0.578 Concordance index (Uno's C-index, overall survival, mean over six trials weighted by evaluated patients; training pool TCGA plus non-trial cohorts plus other trials (largest pool, about 18k samples))
unitless · higher

Uncertainty: Not reported by the source: No interval is printed for this value.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Hallmark GSEA, held-out trials OS Uno C-index, largest training pool

ladon-20261115-protocol-trials-os-uno-weighted

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 5 (page 9), legend 'Hallmark GSEA 0.578', training stage '+ trials' (about 18k samples)
Configuration: Ladon, ridge Cox fitted on TCGA plus non-trial cohorts and other trials (training-pool study)Protocol: Held-out trials, OS Uno C-index weighted by trial size, TCGA plus non-trial cohorts plus other trials training pool
Dataset subset: Six held-out trials with overall survival
0.636 Concordance index (Uno's C-index, overall survival, mean over six trials weighted by evaluated patients; training pool TCGA plus non-trial cohorts plus other trials (largest pool, about 18k samples))
unitless · higher

Uncertainty: Not reported by the source: No interval is printed for this value.

Coverage: Not reported scored / Not reported eligible

Author-reported evaluation · Source checked
Methods, coverage and source

Ladon, held-out trials OS Uno C-index, largest training pool

ladon-20261115-protocol-trials-os-uno-weighted

Aggregation: Not reported

Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF) · Figure 5 (page 9), legend 'Ladon 0.636', training stage '+ trials' (about 18k samples)

Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.

Research readiness

0 of 4 readiness checks met. These checks assess whether the evidence supports a reproducible investigation; a source-checked score alone does not meet them.

Readiness checks, gaps and artifacts

Release 2026-11-21-c8bea25e5abb · Evidence verified: Not verified

Evidence incomplete

Replay metrics

Exact outcomes, predictions, identifiers and evaluator are connected.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified

Verified: Not verified

Evidence incomplete

Investigate discrepancies

Replay evidence includes annotations and an assessment of dependence. Unknown independence permits descriptive analysis only.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Metrics are recomputed from the saved predictions: not yet verified
  • Sample annotations are recorded: not yet verified
  • Dependence between samples is assessed: not yet verified

Verified: Not verified

Evidence incomplete

Run locally

A pinned recipe describes the inputs, environment and resource requirements.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • A pinned run recipe exists: not yet verified
  • Compute requirements are estimated: not yet verified

Verified: Not verified

Evidence incomplete

Validate independently

Separate data and exposure records support an independent test.

Missing or unresolved evidence

  • No verified artifact manifest is linked to this exact record.
  • File checksums match the recorded files: not yet verified
  • Predictions are matched to the right samples: not yet verified
  • Score meaning and direction are confirmed: not yet verified
  • Independent validation data exist: not yet verified
  • Overlap with training data is checked: not yet verified

Verified: Not verified

Readiness describes the evidence in this release. Availability on your computer is checked separately when an investigation runs. Existing data exposure can prevent independent validation even when files are available.

Artifacts and reproduction

No verified artifact manifest is connected to this record yet. The gaps above identify what is needed before analysis can begin.

Subset and evaluation context

This record describes a particular subset or cohort used in an evaluation. Its results do not describe the full dataset.

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

10 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-11-21-c8bea25e5abb
Property and statementOriginal source and locationReview and provenance
Limitations
1 values
  • Patient counts per trial are printed only for OAK (699) and POPLAR (192 RNA-profiled).
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.limitations

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Source dataset
ladon-20261115-data-held-out-trials
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.source_dataset

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Source location
Page 13 trial table; Figure 5 caption
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.source_locator

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Split
Evaluation only
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.split

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Subset scope
OAK and POPLAR (non-small-cell lung), IMpower133 (small-cell lung), IMvigor010 and IMvigor210 (urothelial), IMbrave150 (hepatocellular)
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.subset_scope

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Version
As described in the Ladon technical report
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: attributes.version

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Description
OAK, POPLAR, IMpower133, IMvigor010, IMvigor210 and IMbrave150, evaluated for overall survival.
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: description

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Relationship: used in
ladon-20261115-protocol-trials-os-hazard-ratio
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: links:used_in:ladon-20261115-protocol-trials-os-hazard-ratio

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Relationship: used in
ladon-20261115-protocol-trials-os-uno-weighted
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: links:used_in:ladon-20261115-protocol-trials-os-uno-weighted

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Name
Six held-out trials with overall survival
Context-only references
Ladon: An RNA Foundation Model for Predicting Patient Outcomes (Zenodo PDF)

Original source ↗

Page 13 trial table; Figure 5 caption

Version: Zenodo record 24157116 (version DOI 10.5281/zenodo.24157116; concept DOI 10.5281/zenodo.24157115), file Ladon-An-RNA-Foundation-Model-for-Predicting-Patient-Outcomes.pdf, 47 pages, dated 12 November 2026
Retrieved: 2026-11-15T20:29:10Z

not individually reviewed

No individual claim review recorded

Audit details

Field: name

Source artifact SHA-256: 64edf7c3c956c50a65aa01a0dcaa13f0cfef28ab4373ecfd50c431e67143893c

Hash scope: Hash scope not separately documented; inspect source record

Sources and history

Release 2026-11-21-c8bea25e5abb · Record review: source checked

1 source record and release historyDownload this release (gzip)
Technical metadata and record identifiers

Technical metadata for this record is tracked under stable ID ladon-20261115-data-trials-os-six.

Source locator: Page 13 trial table; Figure 5 caption

Related records

Suggest a correction